Literature DB >> 23543154

Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.

Marlies E H M Van Hoef.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23543154      PMCID： PMC3660000          DOI： 10.3324/haematol.2012.082271

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.

Authors:  P Kebriaei; R M Saliba; C Ma; C Ippoliti; D R Couriel; M de Lima; S Giralt; M H Qazilbash; J L Gajewski; C S Ha; R E Champlin; I F Khouri
Journal:  Bone Marrow Transplant       Date:  2006-06-26       Impact factor: 5.483

2.  Rituximab reduces the incidence of acute graft-versus-host disease.

Authors:  Maximilian Christopeit; Vincent Schütte; Sebastian Theurich; Thomas Weber; Wilfried Grothe; Gerhard Behre
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

3.  Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.

Authors:  Malte von Bonin; Uta Oelschlägel; Jörgen Radke; Michelle Stewart; Gerhard Ehninger; Martin Bornhauser; Uwe Platzbecker
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

4.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.

Authors:  Marijke R Canninga-van Dijk; Hanneke M van der Straaten; Rob Fijnheer; Cornelus J Sanders; Jan G van den Tweel; Leo F Verdonck
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

5.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.

Authors:  Voravit Ratanatharathorn; Lois Ayash; Christopher Reynolds; Samuel Silver; Pavan Reddy; Michael Becker; James L M Ferrara; Joseph P Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2003-08       Impact factor: 5.742

6.  Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.

Authors:  Suzanne van Dorp; Floor Pietersma; Matthias Wölfl; Leo F Verdonck; Eefke J Petersen; Henk M Lokhorst; Edwin Martens; Matthias Theobald; Debbie van Baarle; Ellen Meijer; Jürgen Kuball
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-16       Impact factor: 5.742

7.  Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Authors:  Issa F Khouri; Peter McLaughlin; Rima M Saliba; Chitra Hosing; Martin Korbling; Ming S Lee; L Jeffrey Medeiros; Luis Fayad; Felipe Samaniego; Amin Alousi; Paolo Anderlini; Daniel Couriel; Marcos de Lima; Sergio Giralt; Sattva S Neelapu; Naoto T Ueno; Barry I Samuels; Fredrick Hagemeister; Larry W Kwak; Richard E Champlin
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

8.  Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.

Authors:  Voravit Ratanatharathorn; Brent Logan; Dan Wang; Mary Horowitz; Joseph P Uberti; Olle Ringden; Robert Peter Gale; Hanna Khoury; Mukta Arora; Stephen Spellman; Corey Cutler; Joseph Antin; Martin Bornhaüser; Gregory Hale; Leo Verdonck; Mitchell Cairo; Vikas Gupta; Steven Pavletic
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

9.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

10.  Treatment of refractory chronic GVHD with rituximab: a GITMO study.

Authors:  F Zaja; A Bacigalupo; F Patriarca; M Stanzani; M T Van Lint; C Filì; R Scimè; G Milone; M Falda; C Vener; D Laszlo; P E Alessandrino; F Narni; S Sica; A Olivieri; A Sperotto; A Bosi; F Bonifazi; R Fanin
Journal:  Bone Marrow Transplant       Date:  2007-06-04       Impact factor: 5.483
View more
  3 in total

1.  Reply to: Towards a rational graft-versus-host disease prophylaxis: rituximab should not be forgotten.

Authors:  Christoph M Bucher; Jakob Passweg
Journal:  Haematologica       Date:  2013-04       Impact factor: 9.941

2.  Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects.

Authors:  Heather F Johnston; Yajing Xu; Jeremy J Racine; Kaniel Cassady; Xiong Ni; Tao Wu; Andrew Chan; Stephen Forman; Defu Zeng
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-04       Impact factor: 5.742

Review 3.  Graft-versus-host disease affecting oral cavity. A review.

Authors:  Maria Margaix-Muñoz; José V Bagán; Yolanda Jiménez; María-Gracia Sarrión; Rafael Poveda-Roda
Journal:  J Clin Exp Dent       Date:  2015-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.